Total Payments
$650,655
2024 Payments
$65,733
Companies
28
Transactions
1,063
Medicare Patients
2,980
Medicare Billing
$231,397
Payment Breakdown by Category
Other$473,393 (72.8%)
Travel$64,028 (9.8%)
Research$58,654 (9.0%)
Consulting$28,063 (4.3%)
Food & Beverage$26,212 (4.0%)
Education$304.55 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $473,393 | 171 | 72.8% |
| Travel and Lodging | $64,028 | 188 | 9.8% |
| Unspecified | $58,654 | 19 | 9.0% |
| Consulting Fee | $28,063 | 13 | 4.3% |
| Food and Beverage | $26,212 | 663 | 4.0% |
| Education | $304.55 | 9 | 0.0% |
Payments by Type
General
$592,001
1,044 transactions
Research
$58,654
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $225,384 | 214 | $0 (2019) |
| Amgen Inc. | $148,570 | 142 | $0 (2024) |
| ABBVIE INC. | $128,053 | 292 | $0 (2024) |
| Eli Lilly and Company | $65,626 | 25 | $0 (2021) |
| PFIZER INC. | $63,465 | 59 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $7,055 | 59 | $0 (2024) |
| Dermavant Sciences, Inc. | $4,286 | 28 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,495 | 8 | $0 (2023) |
| Janssen Biotech, Inc. | $1,040 | 31 | $0 (2024) |
| Galderma Laboratories, L.P. | $636.69 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,733 | 176 | PFIZER INC. ($37,808) |
| 2023 | $107,284 | 205 | Amgen Inc. ($78,483) |
| 2022 | $26,571 | 91 | Amgen Inc. ($25,092) |
| 2021 | $16,754 | 68 | Amgen Inc. ($7,826) |
| 2020 | $21,879 | 19 | Amgen Inc. ($11,503) |
| 2019 | $94,184 | 87 | Celgene Corporation ($42,579) |
| 2018 | $153,966 | 197 | Celgene Corporation ($85,186) |
| 2017 | $164,284 | 220 | Celgene Corporation ($97,619) |
All Payment Transactions
1,063 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $6.52 | General |
| Category: Inflammation | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.95 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $31.06 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $17.53 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $7.69 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $134.47 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $40.92 | General |
| Category: Dermatology | ||||||
| 11/11/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Dermatology | ||||||
| 11/04/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $8.21 | General |
| Category: Inflammation | ||||||
| 11/01/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $33.18 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Dermatology | ||||||
| 10/29/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $41.14 | General |
| Category: Inflammation & Immunology | ||||||
| 10/28/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Inflammation & Immunology | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $131.69 | General |
| Category: Dermatology | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $50.26 | General |
| Category: Dermatology | ||||||
| 10/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $38.65 | General |
| Category: Inflammation | ||||||
| 10/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $32.46 | General |
| Category: Inflammation | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $30.07 | General |
| Category: Immunology | ||||||
| 10/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: Inflammation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $51,197 | 6 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $5,409 | 3 |
| Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | SANOFI US SERVICES INC. | $1,495 | 8 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris | Bausch Health US, LLC | $553.11 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 652 | 988 | $180,817 | $55,830 |
| 2022 | 5 | 82 | 92 | $23,602 | $8,534 |
| 2021 | 7 | 582 | 902 | $94,980 | $32,287 |
| 2020 | 12 | 1,664 | 3,704 | $345,189 | $134,746 |
Total Patients
2,980
Total Services
5,686
Medicare Billing
$231,397
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 221 | $55,964 | $20,107 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 91 | 91 | $35,681 | $9,009 | 25.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 100 | 123 | $24,477 | $8,786 | 35.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 91 | 114 | $19,463 | $7,007 | 36.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 79 | 79 | $20,124 | $5,203 | 25.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 60 | 76 | $14,902 | $2,684 | 18.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 13 | 13 | $3,575 | $1,152 | 32.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 37 | 220 | $3,872 | $1,041 | 26.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 18 | 21 | $1,050 | $550.37 | 52.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 30 | $1,709 | $290.79 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 27 | $6,837 | $2,654 | 38.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $7,450 | $2,427 | 32.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 16 | 19 | $3,781 | $1,485 | 39.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 16 | $2,732 | $1,112 | 40.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,802 | $855.98 | 30.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 166 | 207 | $34,155 | $10,332 | 30.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 99 | 103 | $18,025 | $8,456 | 46.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 99 | 99 | $22,275 | $5,571 | 25.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 105 | 111 | $11,100 | $3,814 | 34.4% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 76 | 344 | $3,440 | $1,947 | 56.6% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 26 | 27 | $3,510 | $1,670 | 47.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 11 | 11 | $2,475 | $497.50 | 20.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 383 | 717 | $118,125 | $39,415 | 33.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 289 | 351 | $78,975 | $25,585 | 32.4% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 211 | 280 | $48,975 | $25,540 | 52.1% |
About Dr. Vandana Madkan, MD
Dr. Vandana Madkan, MD is a Dermatology healthcare provider based in Sugar Land, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2010. The National Provider Identifier (NPI) number assigned to this provider is 1659691772.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vandana Madkan, MD has received a total of $650,655 in payments from pharmaceutical and medical device companies, with $65,733 received in 2024. These payments were reported across 1,063 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($473,393).
As a Medicare-enrolled provider, Madkan has provided services to 2,980 Medicare beneficiaries, totaling 5,686 services with total Medicare billing of $231,397. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Sugar Land, TX
- Active Since 06/11/2010
- Last Updated 07/26/2022
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659691772
Products in Payments
- Otezla (Drug) $351,245
- Humira (Biological) $107,171
- LITFULO (Drug) $35,271
- CIBINQO (Drug) $26,942
- Skyrizi (Biological) $8,061
- TALTZ (Drug) $6,624
- COSENTYX (Biological) $6,242
- SKYRIZI (Biological) $5,064
- VTAMA (Drug) $4,286
- Otezla (Biological) $4,174
- TREMFYA (Drug) $850.76
- RINVOQ (Biological) $665.94
- DUPIXENT (Biological) $656.75
- COSENTYX (Drug) $650.57
- Sotyktu (Drug) $593.08
- OPZELURA (Drug) $510.55
- Bimzelx (Biological) $209.44
- Zoryve (Drug) $202.35
- Ilumya (Biological) $185.76
- ILUMYA (Biological) $176.26
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Sugar Land
Dr. Jennifer Maender, M.d, M.D
Dermatology — Payments: $34,386
Dermatology $34,386
Dr. Lauren Snitzer, M.d, M.D
Dermatology — Payments: $20,826
Dermatology $20,826
Dr. Julie Brantley, Md, MD
Dermatology — Payments: $18,301
Dermatology $18,301
Mr. Scott Mcmenemy, M.d, M.D
Dermatology — Payments: $12,390
Dermatology $12,390
Payal Dixit, D.o, D.O
Dermatology — Payments: $10,756
Dermatology $10,756
Chi Tran, M.d, M.D
Dermatology — Payments: $7,398
Dermatology $7,398